Application Progress of High Intensity Focused Ultrasound in Advanced Liver Cancer
Main Article Content
Abstract
High intensity focused ultrasound is a safe, noninvasive, accurate, and repeatable treatment modality that has received extensive attention in tumor therapy. Liver cancer, a malignant tumor of the digestive tract, has high incidence, insidious onset, high recurrence rate, and poor prognosis, and effective treatment methods are still lacking. High intensity focused ultrasound therapy provides a novel mechanism and a new method for the treatment of liver cancer. When combined with arterial interventional therapy, ablation therapy, radiotherapy, and systemic therapy, the efficacy is significantly improved, benefiting more patients. This paper reviews the basic principles of high intensity focused ultrasound therapy and discusses its efficacy and combined treatment effects for advanced liver cancer.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
F. Bray, M. Laversanne, H. Sung, et al., “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 74, no. 3, pp. 229–263, May/Jun. 2024.
B. Han, R. Zheng, H. Zeng, et al., “Cancer incidence and mortality in China, 2022,” J. Natl. Cancer Cent., vol. 4, no. 1, pp. 47–53, Feb. 2024.
R. Zheng, S. Zhang, H. Zeng, et al., “Cancer incidence and mortality in China, 2016,” J. Natl. Cancer Cent., vol. 2, no. 1, pp. 1–9, Feb. 2022.
“Primary liver cancer diagnosis and treatment guidelines (2024 edition),” J. Compr. Cancer Ther. (Electron. Ed.), vol. 10, no. 3, pp. 17–68, 2024.
J. Wang and L. Zhang, “Focused ultrasound ablation therapy for liver cancer,” J. North Sichuan Med. Coll., vol. 38, no. 11, pp. 1451–1454+1474, 2023.
A. Sofuni, H. Takeuchi, K. Sugimoto, et al., “High-intensity focused ultrasound treatment for hepatocellular carcinoma,” J. Med. Ultrason., Jun. 28, 2024.
A. De Maio, G. Alfieri, M. Mattone, et al., “High-intensity focused ultrasound surgery for tumor ablation: a review of current applications,” Radiol. Imaging Cancer, vol. 6, no. 1, art. no. e230074, Jan. 2024.
M. S. Wu and L. L. Liang, “Research progress of high-intensity focused ultrasound thermal ablation in the treatment of abdominal malignant tumors,” Life Sci. Instrum., vol. 22, no. 6, pp. 118–120, 2024.
Y. B. Wang, H. S. Zeng, H. Salameen, et al., “High-intensity focused ultrasound versus transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis,” Int. J. Radiat. Biol., vol. 99, no. 12, pp. 1879– 1889, 2023.
Z. B. Wang, “Focused ultrasound ablation surgery: past, present and future,” Chin. J. Pract. Gynecol. Obstet., vol. 40, no. 9, pp. 872–875, 2024.
X. Chen, Y. Ma, J. Zhang, et al., “Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study,” Int. J. Hyperthermia, vol. 39, no. 1, pp. 1245–1253, 2022.
L. Xiao, D. Cao, and Z. Wu, “Research progress of high-intensity focused ultrasound in remodeling tumor immune microenvironment and anti-tumor therapy,” Prog. Cancer, vol. 22, no. 13, pp. 1397–1401, 2024.
S. Y. Xie and C. B. Jin, “Application and prospect of focused ultrasound ablation therapy in elderly patients with primary liver cancer,” Adv. Clin. Med., vol. 15, no. 2, pp. 1614–1619, 2025.
F. Fazlollahi and M. S. Makary, “Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors,” World J. Radiol., vol. 17, no. 1, art. no. 98618, Jan. 2025.
S. Wu and Y. Guo, “Application progress of high-intensity focused ultrasound technology in malignant tumors,” China Mod. Doctor, vol. 63, no. 13, pp. 118–121, 2025.
D. Sarkar, G. Carbonella, S. Chivi, et al., “Abstract No. 159 combination therapy transarterial ethanol lipiodol embolization and percutaneous microwave ablation of unresectable intermediate to large sized hepatocellular carcinoma,” J. Vasc. Interv. Radiol., vol. 34, no. 3, pp. S74–S74, Mar. 2023.
W. Qiao, Y. Yu, Y. Huang, et al., “Impact of focused ultrasound on the ethanol ablation of VX2 liver tumours in rabbits,” Eur. Radiol., vol. 30, no. 11, pp. 5862–5870, Nov. 2020.
X. Zou, C. Zhao, T. Wang, et al., “The clinical efficacy of percutaneous ethanol-lipiodol injection (PEI) combined with high-intensity focused ultrasound (HIFU) for small hepatocellular carcinoma in special or high-risk locations,” Oncol. Transl. Med., vol. 7, no. 4, pp. 172–176, 2021.
M. Ma and M. R. Xie, “Efficacy and adverse reactions of high-intensity focused ultrasound combined with microwave ablation for large liver cancer,” J. Pract. Cancer, vol. 34, no. 11, pp. 1854–1857, 2019.
A. D’Alessio and L. Rimassa, “A new standard for HCC: The high stakes of TACE-immunotherapy combinations,” Med, vol. 6, no. 3, art. no. 100635, Mar. 2025.
X. W. Chang, Y. Cai, Z. Y. Zhao, et al., “Efficacy and safety of high-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma,” Chin. J. Oper. Proced. Gen. Surg. (Electron. Ed.), vol. 19, no. 1, pp. 56–59, 2025.
H. T. Liu, D. D. Wang, and Y. Chen, “Efficacy of high-intensity focused ultrasound ablation in the treatment of intermediate-advanced primary liver cancer,” Clin. Misdiagn. Misther., vol. 36, no. 3, pp. 45–49, 2023.
J. Hu, H. Mao, and Y. He, “Systematic review and meta-analysis of the efficacy and safety of high-intensity focused ultrasound combined with transarterial chemoembolization and transarterial chemoembolization alone in the treatment of liver cancer,” Transl. Cancer Res., vol. 11, no. 6, pp. 1678–1688, Jun. 2022.
K. C. Cuneo and D. J. Herr, “Advances in radiation therapy for primary liver cancer,” Surg. Oncol. Clin. N. Am., vol. 32, no. 3, pp. 415–432, Jul. 2023.
C. Jin, W. Yang, L. Ran, et al., “Feasibility of high-intensity focused ultrasound for hepatocellular carcinoma after stereotactic body radiation therapy: initial experience,” Ultrasound Med. Biol., vol. 46, no. 10, pp. 2744–2751, Oct. 2020.
Z. W. Xu and F. X. Hu, “Clinical observation of high-intensity focused ultrasound knife in the treatment of advanced liver cancer,” Contemp. Med., vol. 27, no. 26, p. 3, 2021.
L. Wu, J. Zhou, W. Zhou, et al., “Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo,” Pathol. Res. Pract., vol. 220, art. no. 153270, Apr. 2021.
X. Yang, Y. Liao, L. Fan, et al., “High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial,” PLoS ONE, vol. 19, no. 7, art. no. e0306595, Jul. 2024.
M. S. Gao, Y. J. Chen, Y. Yao, et al., “Research progress of high-intensity focused ultrasound in the treatment of pancreatic cancer and liver cancer,” Prog. Cancer, vol. 19, no. 22, p. 19, 2021.
M. M. Chen, W. Z. Chen, X. Guo, et al., “Curative effect of Peiyuan Guben decoction combined with focused ultrasound ablation on liver cancer,” J. Hubei Univ. Chin. Med., vol. 25, no. 3, pp. 26–29, 2023.
W. Ju and W. M. Zhou, “Clinical observation of staged oral and external Chinese medicine combined with high-intensity focused ultrasound for primary liver cancer,” Chin. J. Integr. Tradit. West. Med. Liver Dis., vol. 32, no. 10, pp. 888–891, 2022.
X. Y. Meng, J. H. Yang, W. M. Wen, et al., “Attenuation and synergy effect of Hugan Buzu formula combined with oxaliplatin on hepatocellular carcinoma-bearing nude mice and its mechanism,” China Pharm., vol. 35, no. 3, pp. 283–289, 2024.
Q. Q. Zhang, “Construction of thermal ablation sensitizers and enhancement of tumor comprehensive therapy,” Ph.D. dissertation, Huazhong Univ. Sci. Technol., Wuhan, China, 2024.
X. Xiong, H. Zhou, X. Xu, et al., “Ultrasound molecular imaging enhances high-intensity focused ultrasound ablation on liver cancer with B7-H3-targeted microbubbles,” Cancer Med., vol. 13, no. 20, art. no. e70341, Oct. 2024.
R. Y. Guo, “Effect of microbubble-assisted high-intensity focused ultrasound on primary liver cancer and peripheral blood T lymphocytes,” M.S. thesis, Chongqing Med. Univ., Chongqing, China, 2023.
S. Wang, M. Yin, and Z. Xia, “Efficacy and preliminary dose studies of ultrasound-guided sclerotherapy with lauromacrogol for the treatment of implanted hepatic tumors in rabbits,” J. Gastrointest. Oncol., vol. 14, no. 1, pp. 265–277, Feb. 2023.
Y. Cao, “Experimental study of ultrasound-guided injection of lauromacrogol for the treatment of small hepatocellular carcinoma in rabbit VX2 model,” M.S. thesis, Xiamen Univ., Xiamen, China, 2021.
Y. J. Ding, N. S. Li, W. Qiao, et al., “Anhydrous ethanol and lauromacrogol enhanced focused ultrasound ablation of rabbit liver: an experimental study,” Chin. J. Med. Ultrasound (Electron. Ed.), vol. 17, no. 1, p. 6, 2020.